Clinical Trial Update: STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update of STI571 (imatinib) in patients with recurrent or refractory soft tissue sarcoma; the study status is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Gastrointestinal Stromal Tumor
• Ovarian Cancer
• Small Intestine Cancer
• Soft Tissue Sarcoma

Drugs mentioned

• Gleevec (Imatinib)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Endometrial Cancer, Gastrointestinal Stromal Tumor | Phase 1, Phase 2 | Status: COMPLETED